LAS VEGAS, NV--(Marketwired - October 28, 2016) - CV Sciences, Inc. (
The webcast will discuss the Company's initial drug candidate (CVSI-007), which is a chewing gum that combines synthetic CBD and nicotine.
The Company will provide details on webcast access by press release on Thursday, November 3, 2016.
About CV Sciences, Inc.
CV Sciences, Inc. operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and distributing botanical-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in Las Vegas, Nevada and San Diego, California. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
Contact Information:
Contact:
Robert Haag
Managing Director
IRTH Communications
CVSI@irthcommunications.com
866-976-4784